View the full directory of HCI Cancer Center members

  • A. Welm Lab

    Our research focuses on better understanding the tumor-host interactions that facilitate metastasis, with the ultimate goal of discovering new, improved cancer therapies.

    Alana L. Welm, PhD

  • Agarwal Group

    Neeraj Agarwal, MD

  • Angus-Hill Lab

    Melinda L. Angus-Hill, PhD

  • Atanackovic Lab

    The Atanackovic lab focuses on harnessing the human immune system for the fight against cancer, in particular hematologic malignancies such as MM.

    Djordje Atanackovic, MD

  • Ayer Lab

    The Ayer lab is interested in the transcriptional control of cellular proliferation and how these controls are subverted in human malignancy.

    Donald Ayer, PhD

  • Beckerle Lab

    The primary focus of our laboratory's research is examining how cells modulate their behavior in response to both extrinsic and intrinsic signals. This process of signal integration has profound effects on cell migration, morphology, and function—behaviors that, when aberrant, can lead to cancer and other diseases.

    Mary C. Beckerle, PhD

  • Bernard Lab

    The Bernard Lab at Huntsman Cancer Institute is developing new strategies for the classification, detection, and treatment of cancer

    Phil Bernard, MD

  • Bhaskara Lab

    The Bhaskara Lab studies Epigenetics, DNA damage response, DNA repair, DNA replication and chromatin structure.

    Srividya Bhaskara, PhD

  • Bryan Welm Lab

    Our lab is focused on understanding both the normal processes regulating cell fate determination in the breast, and the relationship between cellular differentiation and cancer, in order to discover the complex molecular pathways driving this disease.

    Bryan E. Welm, PhD

  • Cairns Lab

    We are interested in the molecular logic of totipotency—the ability of germ line stem cells and early embryos to become any type of cell. Within this broad and important question, we focus on how chromatin structure and epigenetics helps regulate gene transcription in the germ line and early embryos. We also examine how chromatin/epigenetics is misregulated in cancers.

    Bradley R. Cairns, PhD

  • Camp Lab

    The main focus of research in the Camp Lab is the identification of germ-line genetic variants that increase susceptibility to disease, with specific interests in breast cancer, chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).

    Nicola J. Camp, PhD

  • Cannon-Albright Group
  • Center for HOPE
  • Chandrasekharan Lab

    Mahesh B. Chandrasekharan, PhD

  • Curtin Group
  • Deininger-O'Hare Lab

    Our lab's research program focuses on the biology of myeloproliferative neoplasms and the development of molecularly targeted therapies.

    Michael W. Deininger, MD, PhD, & Thomas O’Hare, PhD

  • Doherty Group

    Jennifer Doherty, MS, PhD

  • Edgar Lab

    Our research focuses on the mechanisms that control cell growth and proliferation in the fruit fly, Drosophila melanogaster.

    Bruce A. Edgar, PhD

  • Engel Lab

    In spite of decades of research, there are few treatment advances for leukemia and lymphomas patients. These life-threatening diseases of the bone marrow are defined by the build up of leukemia cells and failure of normal blood cell development (hematopoiesis).

    Michael E. Engel, MD, PhD, FAAP

  • Evason Lab

    The overarching goal of the Evason laboratory is to investigate mechanisms involved in liver tumorigenesis in order to develop improved therapies to treat this deadly cancer.

    Kimberley J. Evason, MD, PHD

  • Gaffney Lab

    Our team looks at control and response in mycosis fungoides patients and in patients treated in the post-autologous stem cell transplant setting.

    David K. Gaffney, MD, PhD

  • Gertz Lab Research

    The Gertz Lab develops and applies experimental methods that take advantage of next-generation sequencing to create high-resolution maps of gene regulatory networks.

    Jason Gertz, PhD

  • Grossman Lab

    Doug Grossman, MD, PhD

  • Hashibe Group

    Our research is focused on the molecular and global epidemiology of cancers of the head and neck, thyroid, endometrium, ovary, lung, testis, and colorectum.

    Mia Hashibe, PhD

  • Holmen Lab

    The Holmen Lab is focused on defining critical targets in cancer cells that can become the focus for therapeutic intervention.

    Sheri Holmen, PhD

  • Jared Rutter Lab

    Using both broad and deep approaches, our goal is to define the molecules and their interactions that enable robust and responsive cellular metabolic control.

    Jared P. Rutter, PhD

  • Jensen Group
  • KB Jones Lab

    The K. B. Jones Lab is directed by and supports Dr. Jones as he provides care to patients of all ages with bone and soft-tissue sarcomas, performing surgery to remove the cancers and reconstruct the limbs or body wall. 

    Kevin B Jones, MD

  • Kepka
  • Kirchhoff Research Group

    The Kirchhoff Research Group has a collective goal of understanding and improving the health of pediatric, adolescent, and young adult cancer survivors.

    Anne Kirchhoff, PhD

  • McMahon Lab

    Research in the McMahon Lab focuses on the importance of RAS effectors, such as the RAF family of protein kinases and phosphoinositide 3’ (PI3’)-kinases in the aberrant physiology of cancer cells.

    Martin McMahon, PhD

  • Mendoza Lab

    The Mendoza Lab is using recent advances in proteomics and quantitative imaging to understand how extracellular signals impinge on cytoskeletal dynamics and how oncogenic pathway hyperactivation impacts cancer invasion.

    Michelle C. Mendoza, PhD

  • Myers Lab

    Ben Myers, PhD

  • Oliver Lab

    The Oliver Lab focuses on mechanisms of drug response and resistance in lung cancer with the goal of improving treatment options for patients with lung cancer.

    Trudy G. Oliver, BSc (Hons), PhD

  • Rosenblatt Lab

    The Rosenblatt Lab studies both cell death and cell division and the roles that the actin and microtubule cytoskeletons play in both processes. Our lab investigates if epithelial extrusion could drive cell death in order to control cell numbers, and whether this process malfunctions in cancer.

    Jody Rosenblatt, PhD

  • Schiffman Lab

    The Schiffman Lab studies pediatric hereditary cancer syndromes, with a special interest in genetic susceptibility to childhood cancers.

    Joshua D. Schiffman, MD

  • Snyder Lab

    Eric Snyder, MD, PhD

  • Spike Lab

    In the Spike Lab, we are interested in questions at the intersection of stem cells, development, and cancer.

    Benjamin T. Spike, PhD

  • Stewart Lab

    Our laboratory is interested in how genetic programs governing embryonic development are exploited during cancer initiation and progression.

    Rodney Stewart, PhD, MPhil

  • Tavtigian Lab

    Research in the Tavtigian Lab concentrates on two areas of genetic susceptibility to cancer: 1) Identification and characterization of intermediate-risk and high-risk cancer susceptibility genes, and 2) analysis of unclassified variants that are observed during the clinical testing of established high-risk cancer susceptibility genes.

    Sean V. Tavtigian, PhD

  • Ullman Lab

    The Ullman Lab studies the coordination of cell division, with a particular focus on how assembly of nuclear architecture is integrated with other events of cell division.

    Katharine S. Ullman, PhD

  • Ulrich Group
  • VanBrocklin Lab

    The VanBrocklin Lab is interested in identifying novel molecular targets vital for tumor growth and progression and validating these candidates in pre-clinical models in order to develop rational pharmacological intervention strategies for melanoma and NSCLC patients

    Matthew VanBrocklin, PhD

  • Varley Lab

    Our projects involve the development of new molecular methods and bioinformatics approaches to explore the cancer genome and translate our discoveries into clinical tools that improve patient care.

    Katherine E. Varley, PhD

  • Wu Group

    The Wu Group has a shared goal of improving outcomes for children, adolescents, young adults who are affected by cancer, as well as for their families.

    Yelena Wu, PhD